<< Back to News

System Formulary Update
Antiarrhythmics, Class III

Situation

The antiarrhythmics, class III class review and formulary standardization was approved at the January 2021 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: amiodarone, bretylium, dofetilide, dronedarone, ibutilide

 *Note: Sotalol has been omitted from this class review as it was previously reviewed by System Formulary P&T Subcommittee and System P&T Committee. Refer to Beta Blockers, Non-Selective Side by Side Consensus Review for further details.

Assessment/Recommendation

Changes effective: Tuesday March 9, 2021

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Amiodarone tablet, oral solution (extemporaneous), IV solution (vials and premix)
• Dofetilide capsule
• Dronedarone tablet
• Ibutilide IV solution

Note: Stock of these formulary products may vary at individual entities

As a result, the following products will be removed from the UNC Health Medication Formulary:

• Bretylium